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o.com (B.R. ChallAbstract A simple, sensitive, and speciﬁc liquid chromatography tandem mass spectrometry (LC-MS/
MS) method was developed for the quantiﬁcation of desloratadine (DL) in human plasma using
desloratadine-d5 (DLD5) as an internal standard (IS). Chromatographic separation was performed using
an Xbridge C18 column (50 mm 4.6 mm, 5 mm) with an isocratic mobile phase composed of 10 mM
ammonium formate: methanol (20:80, v/v), at a ﬂow rate of 0.7 mL/min. DL and DLD5 were detected
with proton adducts at m/z 311.2-259.2 and 316.2-264.3 in multiple reaction monitoring (MRM)
positive modes, respectively. Liquid–liquid extraction (LLE) method was used to extract the drug and the
IS. The method was validated over a linear concentration range of 5.0–5000.0 pg/mL with a correlation
coefﬁcient of (r2)Z0.9994. This method demonstrated intra- and inter-day precision within 0.7–2.0% and
0.7–2.7%, and an accuracy within 101.4–102.4%, and 99.5–104.8%. DL was found to be stable
throughout the freeze–thaw cycles, bench-top, and postoperative stability studies. This method was
successfully applied in the analysis of plasma samples following oral administration of DL (5 mg) in 35
healthy Indian male human volunteers under fasting conditions.
& 2012 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.ersity. Production and hosting
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Desloratadine is an antihistamine drug used to treat the
symptoms of allergies, such as sneezing, teary eyes, and runny
nose. It is also used to treat skin hives and itching in people
with chronic skin reactions. The molecular formula of desloa-
tadine is C19H19ClN2 with a molecular weight of 310.8. The
chemical name of the desloratadine is 8-chloro-6,11-dihydro-
11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine
and has a structure as described below [1] (Fig. 1). DL is well
absorbed and is extensively metabolized in the human body.
The major metabolite of DL in human plasma and urine is the
glucuronide conjugate of 3-hydroxydesloratadine. We found
that the elimination of DL was gradual (mean t(1/2)¼19.5 h)
Desloratadine Desloratadine-D5
Figure 1 Chemical structures of desloratadine and desloratadine-D5.
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were no statistically signiﬁcant differences in the mean plasma
concentrations in any of the main pharmacokinetic parameters
of rupatadine, DL, and 3-hydroxydesloratadine when admi-
nistered in combination with azithromycin or alone [5,6].
As of now, there have been several methods reported for
quantiﬁcation of DL in rat plasma with LC-MS [7], human
plasma with LC-MS [8–12], LC-MS with nanospray ionization
[13], human plasma with HPLC [14–16], dog plasma with
HPLC [17], pharmaceutical formulation with HPLC [18,19],
and pharmaceutical formulation with electrophorsis [20]. Wen
et al. [8] reported having developed a method using LLE with
a concentration range of 0.1–20 ng/mL. The sensitivity was
improved by Xu et al. [9] with a concentration range of
0.05–10 ng/mL. Among all researchers, Yang et al. [12]
achieved the best results with high sensitivity at a linearity
range of 25–10000 pg/mL with SPE extraction.
The aim of the proposed method is to extract DL in human
plasma by the LLE method with high sensitivity. Moreover,
the analyte is to be compared with the deuterated internal
standard (IS), which is most appropriate to develop in the
bioanalytical method in terms of matrix effect and reprodu-
cibility. The developed method could be useful for application
in clinical and pharmacokinetic studies.2. Materials and methods
2.1. Chemicals and reagents
DL was obtained from Cadila Pharmaceuticals, India. DLD5 was
procured from Clear Synth, India. Ammonium formate and
sodium hydroxide (analytical grade) were purchased from Merck,
Mumbai, India. Methanol, ethyl acetate, and dichloromethane
(HPLC grade) were obtained from J.T. Baker, USA. Human
plasma was procured from Navjeevan Blood Blank, Hyderabad.
Milli Q water was taken from the in-house Milli-Q system.2.2. Instrumentation
The 1200 series HPLC system (Agilent Technologies,
Germany) was used. Mass spectrometric detection was per-
formed using an API 4000 triple quadrupole instrument (ABI-
SCIEX, Toronto, Canada) and using multiple reaction mon-
itoring (MRM). Data processing was performed using the
Analyst 1.4.1 software package (SCIEX).2.3. Detection
Detection was done by turbo ion spray (API) positive mode
with unit resolution. For DL, mass transitions were obtained
from 311.2 m/z (parent ion) to 259.2 m/z (product ion).
Similarly, DLD5 mass transitions were obtained from (316.2
m/z) (parent ion) to 264.3 m/z (product ion).
2.4. Chromatographic conditions
Chromatographic separation was performed using an Xbridge
C18 column (50 mm 4.6 mm, 5 mm) at a temperature of
40 1C. The mobile phase was composed of 10 mM ammonium
formate:methanol (20:80, v/v) at a ﬂow rate of 0.7 mL/min.
Deuterated IS DLD5 was used as the appropriate IS in terms
of chromatography and extractability. DL and DLD5 were
eluted at 0.970.2 min, approximately, with a total run time of
3 min for each sample.
2.5. Preparation of standards and quality control samples
Standard stock solutions of DL (100.0 mg/mL) and DLD5 IS
(100.0 mg/mL) were prepared in methanol. The IS spiking
solutions (10.0 ng/mL) were prepared in reconstitution solu-
tions (10 mM ammonium formate and methanol in the ratio
of 20:80 (v/v) from IS stock solutions. Standard stock solu-
tions and IS spiking solutions were stored in refrigerator
conditions of 2–8 1C until analysis. Standard stock solutions
of DL (100.0 mg/mL) were added to drug-free screened human
plasma to obtain concentration levels of 5.0, 10.0, 200.0,
800.0, 1400.0, 2000.0, 3000.0, 4000.0, and 5000.0 pg/mL for
analytical standards, and 5.0, 15.0, 2500.0, and 3500.0 pg/mL
for quality control (QC) standards, and stored in the freezer at
30 1C until analysis. The aqueous standards were prepared
in a reconstitution solution (10 mM ammonium formate and
methanol in the ratio of 20:80 (v/v) and stored in the
refrigerator at 2–8 1C until analysis.
2.6. Sample preparation
The LLE method was used to isolate DL and DLD5 from
human plasma. For this purpose, 100 mL of DLD5 (10 ng/mL)
and 400 mL of plasma sample were added to the labeled
polypropylene tubes and vortexed brieﬂy for about 5 min.
Thereafter, 100 mL of 0.1 M NaOH solution and 3 mL of
extraction solvent (in the ratio of ethyl acetate:dichloromethane
80:20(v/v)) were added and vortexed for about 10 min. Next,
the samples were centrifuged at 4000 rpm for approximately
5 min at ambient temperature. From each, a supernatant
sample was transferred into labeled polypropylene tubes and
evaporated to a dryness of 40 1C brieﬂy, and then reconstituted
with a reconstitution solution (10 mM ammonium formate and
methanol in the ratio of 20:80 (v/v), and the sample was
transferred into auto sampler vials and injected into the LC-MS
for study.
2.7. Selectivity and sensitivity
Selectivity was performed by analyzing human blank plasma
samples from six different sources (donors) with an additional
hemolyzed group and lipedimic group to test for interference
V.S. Ponnuru et al.182at the retention times of analytes. The sensitivity was com-
pared with the lower limit of quantiﬁcation (LLOQ) of the
analyte with its blank plasma sample. The peak area of blank
samples should not be more than 20% of the mean peak area
of the limit of quantiﬁcation (LOQ) of DL and 5% of the
mean peak area of DLD5.
2.8. Precision and accuracy
It was determined by replicate analysis of QC samples (n¼6)
at LLOQ, low QC (LQC), medium QC (MQC), high QC
(HQC), and upper limit of quantiﬁcation (ULOQ) levels. The
% coefﬁcient of variation (CV) should be less than 15%, and
accuracy within 15%, except for LLOQ, where it should be
within 20%.
2.9. Matrix effect
The matrix effect caused due to the plasma matrix was used to
evaluate the ion suppression/enhancement in a signal when
comparing the absolute response of QC samples after pre-
treatment (LLE) with the reconstitution samples extracted
from the blank plasma sample spiked with analyte. Experi-
ments in triplicates were performed at MQC levels with 6
different plasma lots with the acceptable precision (% CV) of
r15%.
2.10. Recovery
The extraction recovery of analyte and IS from human plasma
was determined by analyzing QC samples. Recovery at 3
concentrations (15.0, 2500.0, and 3500.0 pg/mL) was deter-
mined by comparing peak areas obtained from the plasma
sample and the standard solution spiked with the blank
plasma residue. A recovery of more than 50% was considered
adequate to obtain required sensitivity.
2.11. Stability
LQC and HQC samples (n¼6) were retrieved from deep freeze
after 3 freeze-thaw cycles according to clinical protocol.
Samples were stored at 30 1C in 3 cycles of 24, 36, and
48 h. In addition, the long-term stability of DL in QC samples
was also evaluated by analysis after 105 days of storage at
30 1C. Auto-sampler stability was studied following a 53-h
storage period in the auto sampler tray with control concen-
trations. Room temperature stability was studied over a 24.5-h
period with control concentrations. Stability samples were
processed and extracted along with the freshly spiked calibra-
tion curve standards. The precision and accuracy for the
stability samples must be withinr15 and715%, respectively,
of their nominal concentrations.
2.12. Analysis of Human samples
The bioanalytical method described above was used to
determine DL concentrations in plasma following oral admin-
istration of healthy human volunteers. These volunteers were
contracted by the APL Research Pvt. Ltd., Hyderabad, India,
and each subject was administered a 5-mg dose (one 5 mg
tablet). This was performed in 35 healthy volunteers throughoral administration along with 240 mL of drinking water. The
reference product, Clarinex tablets (Merck) 5 mg, USA, and
test product, DL tablets (test tablet) 5 mg, were used. Study
protocol was approved by IEC (Institutional Ethical commit-
tee) as per ICMR (Indian Council of Medical Research).
Blood samples were collected at the predose 0 h 5 min prior to
dosage followed by further samples at 0.333, 0.667, 1, 1.333,
1.667, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 18, 24, 48, and
72 h. After dosage, 2 mL blood was collected each time in
vaccutainers containing K2EDTA. A total of 44 (22 time
points for test, and 22 time points for reference) time points
were collected using centrifugation at 3200 rpm, 10 1C, for
10 min, and kept stored at 30 1C until sample analysis. Test
and reference were administered separately to the same human
volunteers under fasting conditions with proper washing
periods as per protocol approved by the IEC.2.13. Pharmacokinetics and statistical analysis
Pharmacokinetics parameters from the human plasma samples
were calculated by a noncompartmental statistics model using
WinNon-Lin5.0. software (Pharsight, USA). Blood samples
were taken during a period of 3–5 times the terminal elimina-
tion half-life (t1/2), and it was considered as the area under the
concentration time curve (AUC) ratio higher than 80%, as per
FDA guidelines. Plasma DL concentration-time proﬁles were
visually inspected, and Cmax and tmax values were determined.
The AUC0–t was obtained by the trapezoidal method. AUC0–N
was calculated up to the last measureable concentration, and
extrapolations were obtained using the last measureable con-
centration and the terminal elimination rate constant (Ke). The
terminal elimination rate constant, (Ke), was estimated from the
slope of the terminal exponential phase of the plasma of DL
concentration time curve (by means of the linear regression
method). The terminal elimination half-life, t1/2, was then
calculated as 0.693/Ke. Regarding AUC0t and Cmax, bioequi-
valence was assessed by means of analysis of variance
(ANOVA) and the standard 90% conﬁdence intervals (CIs
90%) of the ratios’ test/reference (logarithmically transformed
data) was calculated. The bioequivalence was considered
when the ratio of averages of log transformed data was within
80–125% for AUC0t, AUC0N, and Cmax [21,22].3. Results and discussion
3.1. Method development
During development of the method, different options were
evaluated to optimize mass spectrometry detection para-
meters, chromatography, and sample extraction.3.1.1. Mass spectrometry detection parameters optimization
Electrospray ionization (ESI) provided a maximum response
over atmospheric pressure chemical ionization (APCI) mode,
and was chosen for this method. The instrument was opti-
mized to obtain sensitivity and signal stability during infusion
of the analyte in the continuous ﬂow of mobile phase to
electrospray ion source operated at both polarities at a ﬂow
rate of 5 mL/min. DL gave a better response when in the
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predominant peaks in the primary ESI spectra of DL and
DLD5 correspond to the (MþH)þ ions at m/z 311.2 andFigure 2 (A) Parent ion mass spectra of desloratadine and (B)
product ion mass spectra of desloratadine.316.2, respectively (Figs. 2(A) and 3(A)). Product ions of DL
and DLD5 scanned in quadrupole 3 after a collision with
nitrogen in quadrupole 2 had an m/z of 259.2 and 264.3,Figure 3 (A) Parent ion mass spectra of desloratadine-D5 and
(B) product ion mass spectra of desloratadine-D5.
Figure 4 MRM chromatogram of blank human plasma.
V.S. Ponnuru et al.184respectively (Figs. 2(B) and 3(B)). Mass parameters were
optimized as source temperature 500 1C, heater gas 45 psi
(nitrogen), nebulizer gas 30 psi (nitrogen), curtain gas 20 psi
(nitrogen), CAD gas 5 psi (nitrogen), ion spray (IS) voltage
5500 V, source ﬂow rate 600 mL/min without split, entrance
potential 10 V, declustering potential 70 V, collision energy 30 V,
and collision cell exit potential 15 V for both analyte and IS.
3.1.2. Chromatography optimization
Initially, a mobile phase consisting of ammonium acetate and
acetonitrile in varying combinations was tried, but a low response
was observed. The mobile, phase containing 5 mM ammonium
formate, methanol (20:80 v/v), gave a better response, but poor
peak shape was observed. A mobile phase of 0.1% formic acid in
water in combination with methanol and acetonitrile with varying
combinations was tried. Finally, a mobile, phase containing
5 mM ammonium formate, acetonitrile (20:80 v/v), gave the best
signal along with a marked improvement in the peak shape
observed for DL and DLD5. Short-length columns, such as
Symmetry Shield RP18 (50 mm 2.1 mm 3.5 mm), Inertsil
ODS-2V (50 mm 4.6 mm, 5 mm), Hypurity C18 (50 mm 4.6
mm, 5 mm), and Hypurity Advance (50 4.0 mm, 5 mm), Xbridge
C18 (50 mm 4.6 mm, 5 mm), were tried during development of
the method. Xbridge C18 (50 mm 4.6 mm, 5 mm) column gave
a relatively good peak shape with the best signal being obtained.
It gave satisfactory peak shapes for both DL and DLD5. A ﬂow
rate of 0.7 mL/min without splitter was utilized and the run time
was reduced to 2.5 min. Both drug and IS were eluted in a
shorter time at 0.970.2 min. For an LC-MS/MS analysis,
utilization of stable isotope-labeled, or suitable analog drugs
as an IS proved helpful when a signiﬁcant matrix effect is
possible. In our case, DLD5 was found to be best suited for the
present purpose. The column oven temperature was kept at a
constant temperature of about 40 1C. Injection volume of a 5 mL
sample is adjusted for better ionization and chromatography.
3.1.3. Extraction optimization
Prior to loading the sample for LC injection, the coextracted
proteins should be removed from the prepared solution. For this
purpose, initially, we tested with different extraction procedures
like protein precipitation (PPT), LLE, and solid phase extraction
(SPE). We found an ion-suppression effect in the PPT method
for the drug and IS. Further, we also tried this with SPE and
LLE. Out of all these, we observed that LLE is suitable for
extraction of the drug and IS. We tried with several organic
solvents (ethyl acetate, chloroform, n-hexane, dichloromethane,
and methyl tertiary butyl ether) individually as well as with
various combinations of LLE to extract analyte from the plasma
sample. In our case, an ethyl acetate:dichloromethane (80:20)
combination served as a good extraction solvent. The auto
sampler wash is optimized as 80% methanol. High recovery and
selectivity was observed in the LLE method. These optimized
detection parameters, chromatographic conditions, and extrac-
tion procedures resulted in reduced analysis time with accurate
and precise detection of DL in human plasma.
3.2. Method validation
A thorough and complete method of validation of metaxalone
in human plasma was carried out following USFDA guide-
lines [23]. The method was validated for selectivity, sensitivity,matrix effect, linearity, precision and accuracy, recovery, and
stability.
3.2.1. Selectivity and speciﬁcity
The analysis of DL and DLD5 using MRM function was
highly selective with no interfering compounds (Fig. 4).
Speciﬁcity was performed using 6 different lots of human
plasma. Chromatograms obtained from plasma spiked with
DL (5.0 pg/mL) and DLD5 (10.0 ng/mL) are shown in Fig. 5.
3.2.2. Matrix effect
The overall precision of the matrix factor is expressed as CV%
and was determined to be 1.34% for DL and 1.41%
for DLD5.
3.2.3. Linearity
Calibration curves were plotted as the peak area ratio (DL/
DLD5) vs. (DL) concentration. Calibration was found to be
linear over the concentration range of 5.0–5000.0 pg/mL. The
% CV was less than 3.2%, and the accuracy ranged from
97.6% to 102.2%. The determination coefﬁcients (r2) were
greater than 0.9994 for all curves (Table 1).
3.2.4. Precision and accuracy
Precision and accuracy for this method were controlled by
calculating the intra- and inter-batch variations at four
concentrations (5.0, 15.0, 2500.0, and 3500.0 pg/mL) of QC
samples in 6 replicates. As shown in Table 2, the intrabatch %
CV was less than 2.0%, and the accuracy ranged from 101.4%
to 102.4%. Interbatch % CV was less than 2.7%, and the
accuracy ranged from 99.5% to 104.8%. These results indicate
Figure 5 Chromatogram of desloratadine, desloratadine-D5 at LOQ level.













5.0 5.1 0.1 1.9 102.0
10.0 9.7 0.3 3.0 97.6
200.0 199.6 6.4 3.2 99.8
800.0 817.2 15.2 1.8 102.2
1400.0 1389.5 19.5 1.4 99.3
2000.0 2006.6 23.1 1.1 100.3
3000.0 2999.7 19.6 0.6 100.0
4000.0 3968.9 75.1 1.8 99.2
5000.0 5026.8 91.6 1.8 100.5
Quantiﬁcation of desloratadine in human plasma by LC-ESI-MS/MS 185the adequate reliability and reproducibility of this method
within the analytical range.
3.2.5. Recovery
The recovery following the sample preparation using the LLE
method was calculated by comparing the peak area ratios of
DL in plasma samples with the peak area ratios of solvent
samples, and was estimated at control levels of DL. The
recovery of DL was determined at three different concentra-
tions of 15.0, 2500.0, and 3500.0 pg/mL, and was found to be
89.6%, 90.2%, and 91.2%, respectively. The overall averagerecovery of DL and DL D5 was found to be 90.3% and
92.5%, respectively.
3.2.6. LOQ and limit of detection
The LOQ was determined at 5 pg/mL. The limit of detection
(LOD) was determined at 50 fg/10 mL injection volume.
3.2.7. Stability
Quantiﬁcation of the DL in plasma which was subjected to 3
freeze-thaw (30 1C up to room temperature) cycles showed
the stability of the analyte. The concentrations ranged from
99.3% to 98.5% of the theoretical values. No signiﬁcant
degradation of the DL was observed even after a 53-h storage
period in the auto sampler tray, and the ﬁnal concentration of
DL was between 97.3% and 103.2% of the theoretical values.
Room temperature stability at 24.5 h was between 98.0% and
99.4% of the theoretical values. In addition, the long-term
stability of DL in QC samples after 105 days of storage at
30 1C was also evaluated. The concentrations ranged from
94.6% to 101.8% of the theoretical values. These results
conﬁrmed the stability of DL in human plasma for at least
105 days at 30 1C (Table 3).
3.3. Application to biological samples
The method validated above was used in the determination of
DL in plasma samples for establishing the bioequivalence of a






Room temperature stability (24.5 h) 15.0 14.770.5 3.4
3500.0 3480.3743.1 1.2
Autosampler sample stability (53 h) 15.0 14.670.5 3.4
3500.0 3614.47256.6 7.1
Long-term stability (105 days) 15.0 14.270.5 3.5
3500.0 3563.7763.4 1.8
Freeze and thaw stability (cycle 3, 48 h) 15.0 14.970.2 1.3
3500.0 3450.2739.1 1.1







CV (%) Accuracy (%) Concentration measured
(n¼30, pg/mL, mean7SD)
CV (%) Accuracy (%)
5.0 5.170.1 2.0 102.4 5.270.1 1.9 104.8
15.0 15.270.3 2.0 101.9 14.970.3 2.0 99.5
2500.0 2535.0721.4 0.8 101.4 2495.2725.1 1.0 99.8
3500.0 3577.1725.2 0.7 102.2 3550.7725.5 0.7 101.4
Figure 6 Mean plasma concentrations of test vs. reference after a
5 mg dose (one 5 mg Tablet) single oral dose (35 healthy
volunteers).
Table 4 Pharmacokinetic data of test vs. reference after a





Cmax (pg/mL) 2079.2 2058.1
AUC0t (pg h/mL) 46,361.8 46,696.0
aUC0a (pg h/mL) 53,250.1 54,025.6
tmax (h) 4.5 5
t1/2 (h) 24.5 24.3
Ke 0.02822 0.02849
AUC0N: Area under the curve extrapolated to inﬁnity.
AUC0t: Area under the curve up to the last sampling time.
Cmax: The maximum plasma concentration.
tmax: The time to reach peak concentration.
Ke: Elimination rate.
V.S. Ponnuru et al.186single 5 mg dose (one 5 mg tablet) in 35 healthy volunteers.
Typical plasma concentration vs. time proﬁles is shown in
Fig. 6. All the plasma concentrations of DL were in the
standard curve region and retained above the 5.0 pg/mL LOQ
for the entire sampling period. Pharmacokinetic details are
represented in Table 4. Test vs. reference Cmax, AUC0t,
AUC0N were 101.1%, 99.3%, and 98.6%, respectively. On
the basis of the pharmacokinetic data obtained from the testand reference values, it can be concluded that the two DL
formulations (reference and test) analyzed are bioequivalent in
terms of rate and extent of absorption.4. Conclusions
The proposed method was ﬁve times higher in sensitivity than
the method reported by Yang et al. [12] and the analyte was
compared with deuterated IS. The method described here is
quick (it requires less than 2.5 min of analysis time), is rugged,
is a reproducible bioanalytical method, and was successfully
applied to the bioequivalence and pharmacokinetic study of
DL in 35 human volunteers after oral administration of 5 mg
tablets under fasting conditions.
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